Lantern Pharma(LTRN)
$0.39-0.04 (-10.16%)
LTRN
Lantern Pharma stock drug pipeline
$0.39
At close:-0.04 (-10.16%)
Want to see LTRN full AI Analyst Report?
Lantern Pharma (LTRN) Drug Pipeline
343 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Lp-284 | Advanced Solid Tumor, Relapsed Or Refractory Lymphomas | Phase I | Recruiting | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | Nov 03, 2023 | ― |
| Olaparib, Spironolactone, Lp-184 | Advanced Solid Tumor, Pancreatic Adenocarcinoma, Nsclc, Metastatic Solid Tumor, Tnbc - Triple-Negative Breast Cancer, Gbm, Ddr Gene Mutation | phase1AndPhase2 | Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors | Jun 23, 2023 | ― |
| Pemetrexed, Carboplatin, Lp-300 | Carcinoma, Non-small-cell Lung, Adenocarcinoma Of Lung | Phase II | Recruiting | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Jul 06, 2022 | ― |
| Irofulven, Prednisolone 10 Mg | Metastatic Castration-Resistant Prostate Cancer Patients | Phase II | Completed | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | Aug 21, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Lp-284 | Phase I | Advanced Solid Tumor, Relapsed Or Refractory Lymphomas | Recruiting | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | Nov 03, 2023 | ― |
| Olaparib, Spironolactone, Lp-184 | phase1AndPhase2 | Advanced Solid Tumor, Pancreatic Adenocarcinoma, Nsclc, Metastatic Solid Tumor, Tnbc - Triple-Negative Breast Cancer, Gbm, Ddr Gene Mutation | Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors | Jun 23, 2023 | ― |
| Pemetrexed, Carboplatin, Lp-300 | Phase II | Carcinoma, Non-small-cell Lung, Adenocarcinoma Of Lung | Recruiting | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Jul 06, 2022 | ― |
| Irofulven, Prednisolone 10 Mg | Phase II | Metastatic Castration-Resistant Prostate Cancer Patients | Completed | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | Aug 21, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Lantern Pharma, Inc. (LTRN) have in its pipeline
Lantern Pharma LTRN is currently developing the following drugs: Lp-284, Olaparib, Spironolactone, Lp-184, Pemetrexed, Carboplatin, Lp-300, Irofulven, Prednisolone 10 Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

